Sirio Pharma Co. Ltd. (SIRIO, China), the global nutraceutical contract development and manufacturing organization (CDMO), has announced the opening of a gummy production plant at its new development and manufacturing facility in Ma’anshan (more than 186 miles west of Shanghai, China). This announcement comes 11 years after SIRIO opened its first gummy facility, also in China. The new site will be built in several phases and form a “Centre of Excellence” covering an enormous 240,000 square meters (2,583,338.5 square feet).
Phase 1 of the site’s construction has recently been completed and features a gummy production plant and its associated building—designed to expedite development and manufacturing of gummy formulations for global customers.
“In the United States and Europe in particular, there is a significant growth potential in gummy formulations—as they are seen as a more consumer friendly dosage form. For many of the branded firms looking to enter this market early with customized formulations, we offer clear advantages,” said Rui Yang, CSO of SIRIO. “We can expedite development and even offer taste testing options during formulation. Alternatively, we also offer ready-to-go formulations for companies that are looking to enter the market quickly—because we have one of the largest ranges of existing gummy formulations of any global business. But as consumers become more discerning, we anticipate branded companies will increasingly need specialist gummy development partners and capabilities.”
The gummy production plant features integrated R&D and will increase production capacity to 2.4 billion gummies per year. SIRIO also expanded its ability to make innovative products such as liquid filled, center-filled, swirled and multi-colored gummies. In addition, SIRIO has hundreds of standard gummy formulation options suitable for market launch in the U.S. and E.U., and vegetarian options including carrageen and pectin, as well as sugar free and low-sugar options.
“The advantage of running an integrated site is that we can develop a much more tailored product for customers, while also expediting development timelines, thanks to a large team of in-house gummy specialists—more than 10 scientists and formulation engineers dedicated to gummies. We anticipate exponential growth for the gummy lines in 2019,” said Yang. “And obviously, with the new capacity we have, we can supply even for the largest of nutraceutical brands.”
Loren Israelsen, president, United Natural Products Alliance (UNPA), on his recent visit to the new facility commented, “I have toured scores of dietary supplement factories around the world, but few equal SIRIO’s new gummy facility in terms of technology, state-of-the-art design and engineering, robotics, and R&D capabilities. This facility boasts world-class R&D and manufacturing and will help customers innovate new formulations for the fast-growing gummy market.”
For more information, visit https://en.siriopharm.com.
